medigraphic.com
ISSN 0210-5187 (Electronic)

2017, Number 2

<< Back Next >>

Med Cutan Iber Lat Am 2017; 45 (2)

Autoinflammatory diseases with cutaneous manifestations

Rodríguez L, Leiro V, Olivares L

Language: Spanish
References: 30
Page: 94-100
PDF size: 311.36 Kb.


ABSTRACT

Autoimmune diseases are a group of recently described pathologies, caused by defects or mutations in genes that regulate the steps of the innate immune response. They are rare diseases and typically begin in childhood. They manifest with recurrent episodes of systemic inflammation represented by fever, arthritis and inflammatory skin lesions, in the absence of pathogens, circulating autoantibodies or antigen-specific T lymphocytes, this differentiates them from autoimmune diseases. Cutaneous manifestations may in some cases represent the main clinical findings of autoimmune diseases. With regard to pathophysiology, although it is not yet fully understood, it is known that there is a dysregulation of the innate immune system leading to systemic hyperinflammation.


REFERENCES

  1. De Jesus AA, Goldbach-Mansky R. Genetically defined autoinflammatory diseases. Oral Dis. 2016; 22: 591-604.

  2. Russo RA, Katsicas MM. Enfermedades autoinflamatorias. Medicina (B. Aires). 2016; 76: 166-172.

  3. de Jesus AA, Canna SW, Liu Y, Goldbach-Mansky R. Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu Rev Immunol. 2015; 33: 823-874.

  4. Moghaddas F, Masters SL. Monogenic autoinflammatory diseases: cytokinopathies. Cytokine 2015; 74: 237-246.

  5. Beer HD, Contassot E, French LE. The inflammasomes in autoinflammatory diseases with skin involvement. J Invest Dermatol. 2014; 134: 1805-1810.

  6. Krause K, Grattan CE, Bindslev-Jensen C, Gattorno M, Kallinich T, de Koning HD et al. How not to miss autoinflammatory diseases masquerading as urticaria. Allergy. 2012; 67: 1465-1474.

  7. Simon A, Asli B, Braun-Falco M, De Koning H, Fermand JP, Grattan C et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy. 2013; 68: 562-568.

  8. Iglesias A, Panqueva U, Toro C, Mejía J, Rondón F, Restrepo JF y cols. Enfermedad de Still: una perspectiva histórica y una revisión actual. Rev Colomb Reumatol. 2008; 15: 197-206.

  9. Díez MC, Pantoja ZL. Aspectos actuales de la enfermedad de Still del adulto. Med Clin (Barc). 2014; 142: 29-32.

  10. Reddy S, Jia S, Geoffrey R, Lorier R, Suchi M, Broeckel U et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med. 2009; 360: 2438-2444.

  11. Naik HB, Cowen EW. Autoinflammatory pustular neutrophilic diseases. Dermatol Clin. 2013; 31: 405-425.

  12. Cowen EW, Goldbach-Mansky R. DIRA, DITRA, and new insights into pathways of skin inflammation: what’s in a name? Arch Dermatol. 2012; 148: 381-384.

  13. Onoufriadis A, Simpson MA, Pink AE, Di Meglio P, Smith CH, Pullabhatla V et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011; 89: 432-437.

  14. Jordan CT, Cao L, Roberson ED, Pierson KC, Yang C, Joyce CE et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012; 90: 784-795.

  15. Polat A, Demirkaya E, Basbozkurt G, Gattorno M, Ozen S. A glance at history and future perspectives of childhood autoinflammatory disorders. Ann Paediatr Rheum. 2012; 1: 17-30.

  16. Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet. 2002; 11:961-969.

  17. Padeh S, Brezniak N, Zemer D, Pras E, Livneh A, Langevitz P et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome: clinical characteristics and outcome. J Pediatr. 1999; 135: 98-101.

  18. Gurung P, Kanneganti TD. Autoinflammatory skin disorders: the inflammasomme in focus. Trends Mol Med. 2016; 22: 545-564.

  19. Gül A. Approach to the patients with inadequate response to colchicine in familial mediterranean fever best pract. Res Clin Rheumatol. 2016; 30: 1-8.

  20. Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre-Sanchez GA et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014; 371: 507-518.

  21. Kim H, Montealegre SG, Goldbach-Mansky R. Insights from mendelian interferonopathies: comparison of CANDLE, SAVI with AGS, monogenic lupus. J Mol Med. 2016; 10: 1111-1127.

  22. Rice G, Newman WG, Dean J, Patrick T, Parmar R, Flintoff K et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet. 2007; 80: 811-815.

  23. Cavalcante MP, Brunelli JB, Miranda CC, Novak GV, Malle L, Aikawa NE et al. CANDLE syndrome: chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature-a rare case with a novel mutation. Eur J Pediatr. 2016; 175: 735-740.

  24. Kahlenberg JM. Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade. Curr Opin Rheumatol. 2016; 28: 197-203.

  25. Galimberti RL, Vacas AS, Bollea GM, Torre AC. The role of interleukin-1β in pyoderma gangrenosum. JAAD Case Rep. 2016; 2 (5): 366-368. doi: 10.1016/j.jdcr.2016.07.007 PMCID: PMC5043387

  26. Ostring GT, Singh GD. Periodic fevers and autoinflammatory syndromes in childhood. J Paediatr Child Health. 2016; 52: 865-871.

  27. ter Haar NM, Oswald M, Jeyaratman J, Anton J, Barron KS, Brogan PA et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015; 74: 1636-1644.

  28. Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol. 2006; 142: 1591-1597.

  29. Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 2012; 64: 2375-2386.

  30. Yokota S, Kikuchi M, Nozawa T, Kisawa T, Kanetaka T, Miyamae T et al. An approach to the patients with cryopyrin-associated periodic syndrome (CAPS): a new biologic response modifier, canakinumab. Nihon Rinsho Meneki Gakkai Kaishi. 2012; 35: 23-29.




2020     |     www.medigraphic.com